Replies to post #5373 on RespireRx Pharmaceuticals Inc (fka RSPI)

[gfp927z]

For example, here's something Garren just said about CX-717 in his newsletter -

>>> The company repeated and expanded those studies and came to the conclusion that the pathological changes had nothing to do with 717 but with the tissue fixation protocol. <<<


But in fact, CX-717 is a requirement for the phenomenon to occur. The phenomenon doesn't occur in animals not exposed to CX-717, or in animals dosed at lower levels of CX-717. Garren's comment makes it sound like it's just a fixative phenomenon, completely independent of CX-717. Garren should have used Dr. Stoll's more accurate description - that it's a post-mortem only phenomenon.